The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Gene Therapy On Neurological Diseases Market Over The Period 2026–2030?
The market for gene therapy on neurological diseases has expanded swiftly in recent years. It is anticipated to grow from $3.55 billion in 2025 to $4.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. The expansion observed in the past can be ascribed to several factors, including the restricted gene therapy options for neurological diseases, the rising prevalence of alzheimer’s and parkinsons disease, the prevailing dependence on conventional treatment methods, increased awareness of genetic approaches, and early clinical trials involving viral vectors.
The gene therapy on neurological diseases market is projected for significant expansion in the coming years, reaching $6.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This anticipated growth is driven by several factors, including advancements in adeno-associated virus and lentiviral treatments, the broadening of non-viral delivery methods, more regulatory approvals for neurological gene therapies, increased research and development funding for specific genetic interventions, and the incorporation of digital monitoring alongside AI-powered patient management systems. Key trends during this period are expected to encompass greater investment in both viral and non-viral gene therapy platforms, a wider application of gene therapy in various neurological conditions, an enhanced emphasis on customized and precise genetic treatments, the expansion of gene therapy initiatives within hospitals and clinics, and the innovation of sophisticated delivery techniques for neurological gene therapy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp
Which Economic Or Industry Drivers Are Impacting The Gene Therapy On Neurological Diseases Market?
The expanding occurrence of neurological disorders is anticipated to stimulate the development of the gene therapy on neurological diseases market. These conditions are medical ailments impacting the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory deficits. The rise in neurological disorders is connected to the aging demographic, given that aging progressively hinders neuronal operation, diminishes brain adaptability, and heightens oxidative stress, thus fostering the onset and advancement of these conditions. Gene therapy for neurological diseases assists in managing these disorders by addressing their underlying genetic origins, thereby providing potential long-lasting or permanent therapeutic options. This approach enhances patient results through the restoration or alteration of gene function, alleviating symptoms, and decreasing the necessity for repeated procedures, consequently elevating the overall quality of life. An example illustrates this: in July 2024, figures from the National Health Service, a UK government body, indicated 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024. This represented an increase of 3,155 cases when compared to May 31, 2024. Consequently, the growing incidence of neurological disorders is fueling expansion in the gene therapy on neurological diseases market.
How Is The Gene Therapy On Neurological Diseases Market Divided Into Its Major Segments?
The gene therapy on neurological diseases market covered in this report is segmented –
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)
How Are Trends Transforming The Gene Therapy On Neurological Diseases Market Landscape?
Leading companies within the gene therapy market for neurological diseases are concentrating on developing sophisticated viral delivery platforms, such as the adeno-associated virus serotype 2 (AAV2) vector. This focus aims to enhance targeted gene delivery, boost efficacy, minimize immune responses, and enable enduring treatments. The adeno-associated virus serotype 2 (AAV2) vector is recognized as a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into particular cells, especially neurons, for long-term gene expression. For example, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the US, secured U.S. Food and Drug Administration (FDA) approval for its gene therapy intended for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This particular therapy utilizes an AAV2 vector to introduce a working copy of the DDC gene into the putamen, facilitating dopamine production and enhancing motor functions. It is administered as a single, intraputaminal infusion designed to deliver ongoing therapeutic advantages, markedly improving motor function and alleviating severe symptoms without requiring subsequent interventions.
Who Are The Prominent Organizations Shaping The Gene Therapy On Neurological Diseases Market?
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Read the full gene therapy on neurological diseases market report here:
What Are The Top-Performing Regions Within The Gene Therapy On Neurological Diseases Market?
North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Gene Therapy On Neurological Diseases Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp
Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company
Switchboard Market Report 2026
https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report
Mobile Computer Market 2026
https://www.thebusinessresearchcompany.com/report/mobile-computer-market
Surfing Boards Market Report 2026
https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model